|
Variables
|
Univariate
|
Multivariate
|
|---|
|
HR
|
95% CI
|
P
|
HR
|
95% CI
|
P
|
|---|
|
Age (years)
|
|
< 60 yr
|
1.000
| | |
1.000
| | |
|
≥ 60 yr
|
1.540
|
1.107–2.141
|
0.010
|
1.418
|
1.000–2.011
|
0.050
|
|
Sex
|
|
Male
|
1.000
| | | | | |
|
Female
|
1.105
|
0.777–1.571
|
0.577
| | | |
|
BMI
|
|
< 23
|
1.000
| | | | | |
|
≥ 23
|
1.020
|
0.735–1.417
|
0.905
| | | |
|
Surgical approach
|
|
Traditional open
|
1.000
| | | | | |
|
Laparoscopic-assisted
|
0.918
|
0.640–1.318
|
0.644
| | |
0.769
|
|
Intraoperative blood loss
|
|
≤ 100 ml
|
1.000
| | |
1.000
| | |
|
>100 ml
|
1.740
|
1.191–2.527
|
0.004
|
1.780
|
1.211–2.617
|
0.003
|
|
Postoperative complications
|
|
Negative
|
1.000
| | | | | |
|
Positive
|
1.551
|
1.001–2.404
|
0.050
| | |
0.729
|
|
Tumor length/diameter
|
|
< 5 cm
|
1.000
| | | | | |
|
≥ 5 cm
|
1.738
|
1.254–2.408
|
0.001
| | |
0.288
|
|
Histological type
|
|
HD/MD/M-LD
|
1.000
| | | | | |
|
LD/MA/SRC
|
1.489
|
1.072–2.068
|
0.018
| | |
0.094
|
|
Vascular tumor embolus
|
|
Negative
|
1.000
| | | | | |
|
Positive
|
1.956
|
1.372–2.789
|
< 0.001
| | |
0.626
|
|
Depth of Invasion (T)
|
|
T1/T2/T3
|
1.000
| | | | | |
|
T4a/T4b
|
2.133
|
1.525–2.983
|
< 0.001
| | |
0.526
|
|
Lymph node metastasis (N)
|
|
N0/N1
|
1.000
| | | | | |
|
N2/N3
|
3.247
|
2.227–4.736
|
< 0.001
| | |
0.336
|
|
TNM
| | |
< 0.001
| | |
< 0.001
|
|
IIA
|
1.000
| | | | | |
|
IIB
|
2.905
|
1.263–6.680
|
0.012
|
2.667
|
1.158–6.142
|
0.021
|
|
IIIA
|
4.375
|
2.067–9.259
|
< 0.001
|
4.579
|
2.162–9.697
|
< 0.001
|
|
IIIB
|
8.092
|
3.817–17.156
|
< 0.001
|
9.092
|
4.277–19.327
|
< 0.001
|
|
IIIC
|
14.987
|
6.776–33.145
|
< 0.001
|
16.948
|
7.627–37.662
|
< 0.001
|
|
Serum CEA level
|
|
≤ 5 ng/ml
|
1.000
| | | | | |
|
>5 ng/ml
|
1.183
|
0.802–1.744
|
0.396
| | | |
|
Serum CA199 level
|
|
≤ 37 U/ml
|
1.000
| | | | | |
|
>37 U/ml
|
1.333
|
1.082–1.644
|
0.007
| | |
0.981
|
|
Adjuvant chemotherapy cycles
| | |
< 0.001
| | |
< 0.001
|
|
Not received (A)
|
1.000
| | |
1.000
| | |
|
7–8 or 10–12 cycles (B)
|
0.459
|
0.301–0.699
|
< 0.001
|
0.386
|
0.247–0.604
|
< 0.001
|
|
4–6 or 6–9 cycles (C)
|
0.504
|
0.314–0.807
|
0.004
|
0.493
|
0.304–0.800
|
0.004
|
|
≤ 3 or 5 cycles (D)
|
1.032
|
0.638–1.670
|
0.897
|
0.870
|
0.530–1.427
|
0.580
|
- Note: HD/MD/M-LD High/Median/Median-Low differentiation adenocarcinoma, LD/MA/SRC Low differentiation adenocarcinoma/Mucinous adeno-carcinoma/ Signet-ring cell carcinoma, HR Hazard ratio, CI Confidence interval. P < 0.05, statistically significant
